Secondary efficacy analyses of the pivotal SEQUOIA-HCM trial continued to favor aficamten, supporting a potential role for another cardiac myosin inhibitor in obstructive hypertrophic cardiomyopathy ...

In a recent study published in Nature Communication, researchers employed artificial intelligence (AI)-driven virtual screening to discover 'F10', a novel cardiac-specific myosin inhibitor for ...

A decade ago, when Courtney Miller of Scripps Research in Florida found that blocking a specific protein can interrupt methamphetamine addiction in mice, it was difficult to imagine drugs targeting ...

In one of two trials that substantially expand clinical evidence with myosin inhibitors in the treatment of hypertrophic cardiomyopathy (HCM), a next-in-class agent beat beta-blockers in first-line ...

Please provide your email address to receive an email when new articles are posted on . Cardiac myosin inhibitors are now recommended as therapy for certain patients with obstructive hypertrophic ...